Patent 12527771

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2025-08-13 · reel 059905/0091 · ASSIGNMENT OF ASSIGNOR'S INTEREST

    RAMACHANDRAN, KISHORE; DEPUE, JEFFREY SCOTT; REISCH, HELGE ALFRED; TIPPARAJU, SURESH KUMAR; TANG, DATONGTAKEDA PHARMACEUTICAL COMPANY LIMITED

    Correspondent: ALISON M. GILLIS

    Transfer of inventor interests to the assignee

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Jeffrey Scott DEPUE
  • Suresh Kumar Tipparaju
  • Helge Alfred REISCH
  • Datong Tang
  • Kishore Ramachandran

All inventors were employed by Takeda Pharmaceutical Co Ltd at the time of filing.

Original assignee

Takeda Pharmaceutical Co Ltd. Takeda Pharmaceutical Co Ltd is a global pharmaceutical company that develops, manufactures, and sells a range of pharmaceutical products. Their primary line of business is the research, development, manufacturing, and marketing of pharmaceutical drugs. They ship products embodying the claims, specifically LIVTENCITYTM (maribavir), which is an antiviral medication for CMV. Takeda Pharmaceutical Co Ltd is currently an operating company.

Assignment timeline

  • 2025-08-13 (executed) / recorded 2025-08-13 — Reel 059905/0091
    • Conveyance: ASSIGNMENT OF ASSIGNOR'S INTEREST
    • Assignor: RAMACHANDRAN, KISHORE; DEPUE, JEFFREY SCOTT; REISCH, HELGE ALFRED; TIPPARAJU, SURESH KUMAR; TANG, DATONG
    • Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • Correspondent: GILLIS, ALISON M., TAKEDA PHARMACEUTICALS INTERNATIONAL, INC., 95 HAYDEN AVENUE, LEXINGTON, MA 02421
    • Context: Transfer of inventor interests to the assignee

The USPTO Assignment Center search at https://assignmentcenter.uspto.gov/ shows no further recorded assignments for US patent 12527771 as of 2026-05-30.

Timeline diagram

timeline
    title Ownership of US 12527771
    2025 : Application filed by Takeda
    2025 : Inventor interests assigned to Takeda
    2026 : Patent granted to Takeda

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. The patent remains with Takeda Pharmaceutical Co Ltd, an operating company that commercializes products related to the patent.
  2. Known asserter in the chain — not present. Takeda Pharmaceutical Co Ltd is not a known NPE.
  3. Repeat correspondent across the chain — not present. Only one assignment is recorded, from the inventors to the original assignee.
  4. Cascading transfers — not present. Only one assignment is recorded.
  5. Pre-litigation transfer — unclear. While there are litigation cases related to this patent family (US case filed in New Jersey District Court, 2:26-cv-04939 and 2:26-cv-04121), the only recorded assignment is from the inventors to the original assignee, which occurred before these cases were filed (2025-08-13 vs. 2026 filings). There is no transfer to a separate entity directly preceding litigation for this specific patent.
  6. Bankruptcy fire-sale — not present. Takeda Pharmaceutical Co Ltd is an active, operating company.
  7. Privateering — not present. There is no indication of a transfer to an NPE for assertion on Takeda's behalf.
  8. Defensive aggregator (anti-NPE) — not present. The patent remains with Takeda Pharmaceutical Co Ltd.

Verdict

Operating-company assertion

The patent remains assigned to Takeda Pharmaceutical Co Ltd, which is an active pharmaceutical company that ships a product embodying the claims (LIVTENCITYTM). While litigation exists for this patent family, it is being asserted by the original operating company, not a separate NPE.

USPTO Assignment Center search for US12527771

Generated 5/30/2026, 6:45:31 PM